NCT00562211

Brief Summary

A new topical anesthetic which contains 5% lidocaine and a disinfection ingredient has been developed and is tested in this study (LidoDyn). The study examines the efficacy of LidoDyn by comparing it with an already proven anesthetic agent (EMLA crème).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P50-P75 for phase_1 pain

Timeline
Completed

Started Nov 2007

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2007

Completed
19 days until next milestone

First Submitted

Initial submission to the registry

November 20, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

November 21, 2007

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2008

Completed
Last Updated

May 6, 2014

Status Verified

November 1, 2007

Enrollment Period

5 months

First QC Date

November 20, 2007

Last Update Submit

May 5, 2014

Conditions

Keywords

children

Outcome Measures

Primary Outcomes (1)

  • Self report assessment of pain (using the Visual Analog Scale)

    60 Min+ 5-10 Min

Secondary Outcomes (1)

  • Medical staff observational assessment of pain (in a scale of 0 to 10)

    60 Min + 5-10 Min

Study Arms (2)

1

EXPERIMENTAL
Drug: LidoDyn

2

ACTIVE COMPARATOR
Drug: EMLA creme

Interventions

Application of 2 gram of LidoDyn to the skin surface the patient's antecubital fossa 60 min prior to venipuncture

1

Application of 2 gram of EMLA creme to the skin surface the patient's antecubital fossa 60 min prior to venipuncture

2

Eligibility Criteria

Age12 Years - 16 Years
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17)

You may qualify if:

  • Previously healthy children of whom venipuncture is needed to be performed.

You may not qualify if:

  • History of allergic reaction to any local anesthetic.
  • History of chronic disease
  • Patient's condition requires urgent treatment (e.g. severe dehydration, shock)
  • Active local skin infection or skin pathologic condition at the antecubital fossa
  • Tattoo, surgical scar or skin condition that might interfere with skin sight assessment.
  • Patient undergone venipuncture at the antecubital fossa within the pror two weeks.
  • Uncooperative or exceptionally anxious patient.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Emergency Department of the Meyer Children Hospital, Rambam Health Care Campus

Haifa, Israel

Location

MeSH Terms

Conditions

Pain

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Itai Shavit, M.D.

    Rambam Health Care Campus

    PRINCIPAL INVESTIGATOR
  • Hadas Knaani-Levinz, M.D.

    Rambam Health Care Campus

    PRINCIPAL INVESTIGATOR
  • Amir Hadash, M.D.

    Rambam Health Care Campus

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Pediatric Emergency Department director

Study Record Dates

First Submitted

November 20, 2007

First Posted

November 21, 2007

Study Start

November 1, 2007

Primary Completion

April 1, 2008

Study Completion

April 1, 2008

Last Updated

May 6, 2014

Record last verified: 2007-11

Locations